amoxicillin/flucloxacillin
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 18, 2025
Treatment of Toxic Epidermal Necrolysis by Plasmapheresis: A Prospective Study
(EADV 2025)
- "Allopurinol was the most frequently implicated drug (50% of cases), followed by flucloxacillin– amoxicillin combination (16.7%), fenoprofen (16.7%), and spiramycin combined with metronidazole (16.7%). Plasmapheresis appears to be a promising therapeutic option in the management of TEN, although current evidence for its efficacy remains limited to isolated case reports and small case series. This technique enables the removal of the offending drug, its metabolites, and immune mediators involved in the inflammatory cascade of TEN. Further studies are needed to confirm its efficacy and establish standardized protocols in the treatment of toxic epidermal necrolysis."
Clinical • Cardiovascular • Coronary Artery Disease • Heart Failure • Infectious Disease • Respiratory Diseases • Septic Shock • Steven-Johnson Syndrome
March 30, 2022
Interaction between posaconazole and flucloxacillin in a lung transplant patient: decrease in plasma exposure of posaconazole and possible undertreatment of invasive aspergillosis: case report.
(PubMed, BMC Pulm Med)
- "We describe a new interaction between posaconazole and flucloxacillin. Presumably the underlying mechanism is activation of the pregnane X receptor by flucloxacillin, which can induce cytochrome P450, uridine glucuronosyl transferase (UGT1A4) and P-glycoprotein. We advise caution when combining flucloxacillin and triazoles, because interactions may lead to undertreatment of invasive aspergillosis."
Journal • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Transplantation
1 to 2
Of
2
Go to page
1